Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells

被引:97
作者
Hölig, P
Bach, M
Völkel, T
Nahde, T
Hoffmann, S
Müller, R
Kontermann, RE
机构
[1] Vectron Therapeut AG, D-35037 Marburg, Germany
[2] Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35033 Marburg, Germany
关键词
drug delivery; integrins; phage display; RGD peptides; vascular targeting;
D O I
10.1093/protein/gzh055
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RGD peptides targeting alpha(v)-integrins are promising ligands for the generation of vascular targeting agents. We isolated from phage display RGD motif libraries novel high-affinity cyclic RGD peptides by selection on either endothelial or melanoma cells. Although the starting sequences contained only two cysteine residues flanking the RGD motif, several of the isolated peptides possessed four cysteine residues. A high-affinity peptide (RGD10) constrained by only one disulfide bond was used to generate novel lipopeptides composed of a lipid anchor, a short flexible spacer and the peptide ligand conjugated to the spacer end. Incorporation of RGD10 lipopeptides into liposomes resulted in specific and efficient binding of the liposomes to integrin-expressing cells. In vivo experiments applying doxorubicin-loaded RGD10 liposomes in a C26 colon carcinoma mouse model demonstrated improved efficacy compared with free doxorubicin and untargeted liposomes.
引用
收藏
页码:433 / 441
页数:9
相关论文
共 37 条
  • [1] Therapeutic cancer targeting peptides
    Aina, OH
    Sroka, TC
    Chen, ML
    Lam, KS
    [J]. BIOPOLYMERS, 2002, 66 (03) : 184 - 199
  • [2] Drug delivery systems: Entering the mainstream
    Allen, TM
    Cullis, PR
    [J]. SCIENCE, 2004, 303 (5665) : 1818 - 1822
  • [3] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
    Arap, W
    Pasqualini, R
    Ruoslahti, E
    [J]. SCIENCE, 1998, 279 (5349) : 377 - 380
  • [4] Solution structures and integrin binding activities of an RGD peptide with two isomers
    Assa-Munt, N
    Jia, X
    Laakkonen, P
    Ruoslahti, E
    [J]. BIOCHEMISTRY, 2001, 40 (08) : 2373 - 2378
  • [5] Antiangiogenic tumour therapy: will it work?
    Augustin, HG
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (06) : 216 - 222
  • [6] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    Boehm, T
    Folkman, J
    Browder, T
    OReilly, MS
    [J]. NATURE, 1997, 390 (6658) : 404 - 407
  • [7] CHERNY RC, 1993, J BIOL CHEM, V268, P9725
  • [8] CONFORTI G, 1992, BLOOD, V80, P437
  • [9] Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy
    DeNardo, SJ
    Burke, PA
    Leigh, BR
    O'Donnell, RT
    Miers, LA
    Kroger, LA
    Goodman, SL
    Matzku, S
    Jonczyk, A
    Lamborn, KR
    DeNardo, GL
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (01) : 71 - 79
  • [10] Drummond DC, 1999, PHARMACOL REV, V51, P691